CYCN - cyclerion.com Real Price to Acquire Entire Company
This chart of Cyclerion Therapeutics (CYCN) quotes demonstrates an Enterprise Value of 14.34. The business focuses on developing brain therapies via sGC activation, distributing projects across various testing stages to minimize risk. The team relies on dedicated neurobiologists and the targeted hiring of experts. The company's success is based on platform efficiency, cash reserves, and strategic alliances.
Cyclerion Therapeutics, Inc. - analytical breakdowns and key metrics (CYCN)
- market value and analyst target forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Capital Cyclerion Therapeutics|CYCN - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Cyclerion Therapeutics Inc.|CYCN - Company Debts|Debt to Net Assets Ratio Cyclerion Therapeutics|CYCN - Company Long-Term Debt|Short-Term Debt Cyclerion Therapeutics|Quick Liquidity Indicator cyclerion.com
- earnings and valuation multiples indicators:
Analysis of all company metrics:Cyclerion Therapeutics
To minimize risks, investors should seek assets with a stable enterprise value, which sums market capitalization and net debt to reflect the actual cost of a full business buyout. When analyzing the enterprise value fluctuations of Cyclerion Therapeutics (CYCN), it is important to consider that maintaining a strong R&D core of neurobiologists supports the company's fundamental value even amidst share price volatility.
Competitors of Cyclerion Therapeutics (CYCN)
Biogen Inc (BIIB) - Total Enterprise Value|Neurocrine Biosciences Inc - Enterprise Value|Regencell Corp (RGC) - Real Price to Acquire Entire Company|Axsome Therapeutics (AXSM) - Total Company Value|Business Value ACAD|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|AVXL (Anavex Life Sciences) - Enterprise Value|Real Price to Acquire Entire Company ceribell.com (CBLL)|Real Price to Acquire Entire Company PRTA (Prothena Biosciences)|ALEC - Total Enterprise Value|Enterprise Value ANNX (Annexon Inc.)|OMER - Real Price to Acquire Entire Company|NGNE - Total Company Value|ACIU: Total Company Value|VYGR: Enterprise Value|Total Enterprise Value Neumora (NMRA)|Total Company Value Scilex Holding Co.|TVGN: Value Adjusted for Debt and Cash|Enterprise Value ACOG|Company Buyout Price Cognition Therapeutics Inc.|Total Company Value Inhibikase Therapeutics, Inc. IKT|Cassava Sciences Inc (SAVA) - Total Enterprise Value|ASRT - Total Company Value|COYA (Coya Therapeutics, Inc.) - Business Value|VTGN (vistagen.com) - Real Price to Acquire Entire Company|Ovid Therapeutics - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company ABOS|CRVO (CervoMed, Inc.) - Aggregate Business Value|Enterprise Value ATHE|CLNN (clene.com) - Value Adjusted for Debt and Cash|Enterprise Value PEPG (PepGen)|Jupiter Neurosciences, Inc. (JUNS) - Total Enterprise Value|RLMD - Total Company Value|Value Adjusted for Debt and Cash ANVS (Annovis Bio Inc)|GRCE: Enterprise Value|Firefly Neuro (AIFF) - Enterprise Value|Total Company Value ANEW Medical|NeuroSense Therapeutics, Ltd. - Full Business Value|Enterprise Value RVPH|MTVA - Total Enterprise Value|NeurAxis, Inc - Real Price to Acquire Entire Company|Enterprise Value Helius Medical Technologies, Inc. HSDT|PASG: Real Price to Acquire Entire Company|Neuphoria Therapeutics Inc. - Aggregate Business Value|NERV: Enterprise Value|ATHA - Company Buyout Price|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value|Real Price to Acquire Entire Company Alzamend (ALZN)|Total Company Value Protagenic Therapeutics (PTIX)|Company Buyout Price pasitheaclinics.com|Enterprise Value CRGT (Cortigent)|ATXI - Real Price to Acquire Entire Company|BCLI: Real Price to Acquire Entire Company|Total Enterprise Value Cara Therapeutics Inc|CHRO: Enterprise Value|Real Price to Acquire Entire Company Eliem Therapeutics Inc.|Total Company Value Intra-Cellular Therapies Inc.|Business Value LBPH (Longboard Pharmaceuticals Inc)|Total Company Value Marinus (MRNS)|NKGen Biotech Corp - Business Value|Enterprise Value NRBO (NeuroBo Pharmaceuticals)|sagerx.com (SAGE) - Total Enterprise Value|SNPX: Real Price to Acquire Entire Company|TRVN - Enterprise Value|vigilneuro.com (VIGL) - Total Company Value|anewmeds.com - Value Adjusted for Debt and Cash|Total Company Value Cerevel Therapeutics